Opportunity Information: Apply for PAR 11 058
Apply for PAR 11 058
- The National Institutes of Health in the environment health income security and social services sector is offering a public funding opportunity titled "Developmental Pharmacology (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Aug 7, 2013 and posted on Dec 3, 2010.
- Applicants must submit their applications by Aug 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: State governments Special district governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Independent school districts County governments Private institutions of higher education Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Developmental Pharmacology (R03) funding opportunity (PAR-11-058) is an NIH small grant announcement aimed at supporting focused, investigator-initiated studies that improve understanding of how drug effects change across childhood development. It is sponsored by multiple NIH components, led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) with participation from the National Cancer Institute (NCI) and the National Institute of Environmental Health Sciences (NIEHS). The central theme is developmental (pediatric) pharmacology, with a strong emphasis on ontogeny, meaning how biological systems involved in drug action and handling mature and shift from fetal life through infancy, childhood, and adolescence. The opportunity is intended to stimulate multidisciplinary basic and translational research, which can include laboratory-based mechanistic work as well as studies that help bridge findings toward clinical relevance in pediatric populations.
Scientifically, the announcement highlights the importance of age-related differences in drug disposition and response that arise from developmental changes in key biological pathways. Priority areas include research on drug-metabolizing enzymes, drug transporters, receptors, and downstream signaling pathways, and how the activity or expression of these systems varies across developmental periods. In practical terms, this kind of work can support safer and more effective medication use for children by clarifying why the same drug may behave differently in a fetus, neonate, toddler, school-age child, or adolescent. Projects under this umbrella might examine developmental regulation of enzyme families and transport proteins, changing receptor sensitivity or density, maturation of organ systems relevant to absorption and clearance, or molecular signaling differences that alter therapeutic response or toxicity risk as children grow.
From an administrative and funding standpoint, this is an R03 mechanism, which is typically designed for smaller, well-scoped projects such as pilot studies, feasibility testing, secondary analyses, or tightly focused mechanistic experiments that can generate preliminary data for larger future studies. The listed award ceiling is $50,000. There is no cost sharing or matching requirement. The opportunity is categorized as discretionary and uses the standard NIH grant funding instrument. It is associated with CFDA numbers 93.113 (Environmental Health), 93.853 (Neurosciences and Neurological Disorders Extramural Research), and 93.865 (Child Health and Human Development Extramural Research), reflecting the cross-cutting relevance of developmental pharmacology to multiple health domains.
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants include state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; small businesses; for-profit organizations (other than small businesses); and nonprofit organizations both with and without 501(c)(3) status (excluding higher education institutions where specified). The announcement also explicitly includes a wide range of additional eligible entities such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, federally recognized and other tribal governments/organizations, U.S. territories or possessions, regional organizations, eligible federal agencies, and foreign (non-U.S.) organizations.
Key dates in the source record show the opportunity was posted on December 3, 2010, with an original closing date of May 7, 2014, and an archive date of September 8, 2013 (the record also lists a current closing date of August 7, 2013 and a creation date of August 7, 2013, which appears to reflect system record updates rather than the original publication timeline). The sponsoring agency is the National Institutes of Health. Applicants are directed to the full announcement for complete requirements and instructions via the NIH grants guide page: http://grants.nih.gov/grants/guide/pa-files/PAR-11-058.html. For technical access or linking issues, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Developmental Pharmacology (R03) (PAR-11-058) - Frequently Asked Questions
What is the Developmental Pharmacology (R03) funding opportunity (PAR-11-058)?
PAR-11-058 is an NIH small grant (R03) opportunity that supports focused, investigator-initiated studies to improve understanding of how drug effects and drug handling change across childhood development. The scientific focus is developmental (pediatric) pharmacology, emphasizing how biology relevant to drugs matures and shifts from fetal life through infancy, childhood, and adolescence.
Which NIH institutes or components sponsor this opportunity?
This opportunity is sponsored by multiple NIH components and is led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), with participation from the National Cancer Institute (NCI) and the National Institute of Environmental Health Sciences (NIEHS).
What is the central scientific theme of this announcement?
The central theme is developmental (pediatric) pharmacology with a strong emphasis on ontogeny, meaning how biological systems involved in drug action and drug disposition mature and change across developmental stages (fetal, neonatal, infant, child, adolescent).
What types of research does this funding opportunity aim to stimulate?
The announcement is intended to stimulate multidisciplinary basic and translational research. This can include laboratory-based mechanistic work as well as studies that help bridge findings toward clinical relevance in pediatric populations.
What kinds of age-related differences in drug response are highlighted?
The opportunity highlights that age-related differences in drug disposition and response can arise from developmental changes in key biological pathways. These differences can explain why the same drug may behave differently in a fetus, neonate, toddler, school-age child, or adolescent.
What are the priority scientific areas mentioned in the announcement?
Priority areas include research on drug-metabolizing enzymes, drug transporters, receptors, and downstream signaling pathways, including how their activity or expression varies across developmental periods.
What are example topics that fit within the scope described?
Examples described include studies on developmental regulation of enzyme families and transport proteins, changing receptor sensitivity or density across age, maturation of organ systems relevant to absorption and clearance, and molecular signaling differences that alter therapeutic response or toxicity risk as children grow.
How can this research support pediatric medication safety and effectiveness?
By clarifying how developing biology influences drug disposition and response, these studies can help explain pediatric differences in therapeutic response or toxicity risk and thereby support safer and more effective medication use for children.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R03 mechanism, which is typically designed for smaller, well-scoped projects.
What kinds of projects are typically appropriate for an R03, based on the description?
R03 projects are typically suitable for pilot studies, feasibility testing, secondary analyses, or tightly focused mechanistic experiments that can generate preliminary data for larger future studies.
What is the award ceiling listed for this opportunity?
The listed award ceiling is $50,000.
Is cost sharing or matching required?
No. The information provided states there is no cost sharing or matching requirement.
What is the funding instrument and how is the opportunity categorized?
The opportunity uses the standard NIH grant funding instrument and is categorized as discretionary.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.113 (Environmental Health), 93.853 (Neurosciences and Neurological Disorders Extramural Research), and 93.865 (Child Health and Human Development Extramural Research).
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants include state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; small businesses; for-profit organizations (other than small businesses); and nonprofit organizations both with and without 501(c)(3) status (excluding higher education institutions where specified).
Are specific institution types explicitly included?
Yes. The announcement explicitly includes organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, federally recognized and other tribal governments/organizations, U.S. territories or possessions, regional organizations, eligible federal agencies, and foreign (non-U.S.) organizations.
Are foreign (non-U.S.) organizations eligible?
Yes. The provided information explicitly states that foreign (non-U.S.) organizations are included among eligible applicants.
What agency is listed as the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
Where can applicants find the full announcement and official instructions?
Applicants are directed to the NIH grants guide page for the complete announcement and requirements: http://grants.nih.gov/grants/guide/pa-files/PAR-11-058.html
What are the key dates shown in the source record?
The record shows the opportunity was posted on December 3, 2010. It lists an original closing date of May 7, 2014. It also lists an archive date of September 8, 2013, and shows a current closing date of August 7, 2013 and a creation date of August 7, 2013, which are noted as likely reflecting system record updates rather than the original publication timeline.
Who is the contact for technical access or linking issues?
For technical access or linking issues, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Environment Health Income Security and Social Services
Next opportunity: Developmental Pharmacology (R21)
Previous opportunity: Developmental Pharmacology (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 11 058
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 11 058) also looked into and applied for these:
| Funding Opportunity |
|---|
| Developmental Pharmacology (R21) Apply for PAR 11 059 Funding Number: PAR 11 059 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) Apply for PAR 11 155 Funding Number: PAR 11 155 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Autism Centers of Excellence Centers (P50) Apply for RFA HD 12 195 Funding Number: RFA HD 12 195 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,500,000 |
| Autism Centers of Excellence Networks (R01) Apply for RFA HD 12 196 Funding Number: RFA HD 12 196 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 058", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.